Investors & Media
News
SAGE Therapeutics Announces Participation in February Conferences
-
Canaccord Genuity Rare Disease, BioPharma 1x1 Day on
Tuesday, Feb. 3, 2015 , inNew York -
Leerink Global Healthcare Conference , with a presentation at11:10 a.m. ET onThursday, Feb. 12, 2015 , inNew York -
SunTrust Robinson Humphrey One-on-One Orphan Drug Day on
Monday, Feb. 23, 2015 inNew York
A live webcast of the
About
Forward-Looking Statements
Various statements in this release concerning SAGE's future expectations, plans and prospects, including without limitation, SAGE's expectations regarding the potential safety, pharmacological effect and efficacy of SAGE-547 as a treatment for SRSE and post-partum depression and essential tremor, the expected development pathway for SAGE-547and SAGE's other product candidates and its expectations with respect to the timing and success of its clinical trials, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, SAGE's ability to successfully demonstrate the efficacy and safety of its product
candidates, the pre-clinical and clinical results for its product candidates, which may not support further development of product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials, obtaining, maintaining and protecting intellectual property, SAGE's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, competition from others developing products for similar uses, SAGE's ability to manage operating expenses, SAGE's ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, SAGE's dependence on third parties for development, manufacture, marketing, sales and distribution of products, the outcome of litigation, and unexpected expenditures, as well as those risks
more fully discussed in the section entitled "Risk Factors" in SAGE's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in SAGE's subsequent filings with the
CONTACT: Media Contact:Source:Dan Budwick ,Pure Communications dan@purecommunicationsinc.com 973-271-6085 Investor Contact:Paul Cox ,SAGE Therapeutics paul.cox@sagerx.com 617-299-837
News Provided by Acquire Media